DrugPatentWatch Database Preview

MOXEZA Drug Profile

« Back to Dashboard

Which patents cover Moxeza, and when can generic versions of Moxeza launch?

Moxeza is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-two countries.

The generic ingredient in MOXEZA is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

Summary for MOXEZA

International Patents:	94
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	63
Patent Applications:	4,143
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for MOXEZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOXEZA
DailyMed Link:	MOXEZA at DailyMed

Pharmacology for MOXEZA

Drug Class

Quinolone Antimicrobial

Synonyms for MOXEZA

(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

1-cyclopropyl-6-fluoro-1,4-dihydro-7-((4aR,7aS)-octahydropyrrolo[3,4-b]pyridin

1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid

1-Cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydro-1H-pyrrolo[3,4-b]pyridin-6(2H)-yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

1-Cyclopropyl-6-Fluoro-8-Methoxy-7-[(4as,7as)-Octahydro-6h-Pyrrolo[3,4-B]pyridin-6-Yl]-4-Oxo-1,4-Dihydroquinoline-3-Carboxylic Acid

151096-09-2

192927-63-2

195154-07-5

3-QUINOLINECARBOXYLIC ACID 1-CYCLOPROPYL-6-FLUORO-1 4-DIHYDRO-8-METHOXY-7-[(4AS 7AS)-OCTAHYDRO-6H-PYRROLO[3 4-B]PYRIDIN-6-YL]-4-OXO-

3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-

3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-

7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid

7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid

7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

96M092

AB0011262

AB00171653_15

AB00171653-11

AB00171653-13

AB00171653-14

AC-25913

AC1L49EP

Actira (*Hydrochloride*)

AJ-45743

AK-75805

AKOS015895251

AM84644

AMX10191

AN-1289

ANW-57564

API0004683

Avalox (TN)

Avelon (TN)

Avelox (*Hydrochloride*)

Avelox (TN)

Avelox I.V.

Avelox IV (TN)

Avolex

AX8043888

BAY 12-8039

BAY 12-8039 (*Hydrochloride*)

BCP0726000137

BCP9000962

BDBM50366824

CCG-221192

CCRIS 8690

CHEBI:63611

CS-1895

CTK8B7522

D08237

D0ZV0Z

DB00218

DTXSID3048491

EX-A016

FABPRXSRWADJSP-MEDUHNTESA-N

HE066848

HE211919

HE313568

HSDB 8026

HY-66011A

I06-1961

Izilox

KB-33277

LS-141510

MFCD04117996

MFX

moxifloxacin

Moxifloxacin (INN)

Moxifloxacin [INN:BAN]

Moxifloxacine

moxyfloxacin

MXF

MXFX

Q-9195

SBI-0206792.P001

SCHEMBL24007

ST2403416

TR-035776

U188XYD42P

UNII-U188XYD42P

Vigamox

Vigamox (TN)

ZINC3826253

US Patents and Regulatory Information for MOXEZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010	AT2	RX	Yes	Yes			Y
Novartis Pharms Corp	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010	AT2	RX	Yes	Yes					Y
Novartis Pharms Corp	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010	AT2	RX	Yes	Yes			Y

Expired US Patents for MOXEZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010
Novartis Pharms Corp	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010

Paragraph IV (Patent) Challenges for MOXEZA

Drugname	Dosage	Strength	RLD	Date
	Ophthalmic Solution	10.5%

International Patents for MOXEZA

Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	0189495
China	103550141
European Patent Office	1117402

Supplementary Protection Certificates for MOXEZA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2000	Austria		PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
C/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
00111	Netherlands		PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621